Physician profile
Steven Peter Maurides
NPI 1447789482
$2,297.81
in general payments reported to CMS, 2019-2025
24 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.73 · 2022: $21.20 · 2023: $358 · 2024: $974 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.00 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $270.68 | 2023-2025 | |
| Philips North America LLC | $263.99 | 2023-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.51 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $182.54 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.67 | 2024-2025 | Jardiance |
| Boston Scientific Corporation | $113.08 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Kiniksa Pharmaceuticals International, Plc | $96.89 | 2024 | Arcalyst |
| Pfizer INC. | $90.58 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.16 | 2024 | Farxiga |
| Abiomed | $61.21 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $54.14 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $49.83 | 2024-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $43.51 | 2024 | |
| Impulse Dynamics (USA) INC. | $32.79 | 2023-2025 | Optimizer, Optimizer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.51 | 2023-2024 | Verquvo |
| Atricure, INC. | $26.50 | 2024 | |
| Novo Nordisk INC | $24.68 | 2024 | Wegovy |
| Daiichi Sankyo INC. | $24.45 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $23.59 | 2024 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $21.48 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $21.20 | 2022 | |
| Glaxosmithkline, LLC. | $19.09 | 2025 | Shingrix |
| Cardiva Medical, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Maurides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.